U.S., March 10 -- ClinicalTrials.gov registry received information related to the study (NCT07457671) titled 'TAR-0520 Gel in Hand and Foot Syndrome' on Feb. 24.

Brief Summary: Hand and Foot Syndrome (HFS) is a weii-established and frequent cutaneous adverse event of capecitabine used in the treatment of different cancers.HFS is charectirized by a variety of symptoms ranging from mild discomfort to a painful sensation of palms and sols that could limit functionality and hamper patients on their daily activities.

The aim of this study is to explore the TAR-0520 gel safety and preventive efficacy of HFS in patients with colorectal and breast cancer patients treated with capecitabine.

Is the product well tolerated locally and systemically ?...